Revolution Medicines (RVMD) CEO Goldsmith sells $18 million in shares

AI Summary

Revolution Medicines (RVMD) CEO Mark Goldsmith sold shares valued at $18 million. This sale reflects a significant transaction that may influence investor sentiment and perceptions of the company's future. The timing and volume of the sale could affect the stock's trading activity in the short term. Such insider trading activity is notable as it can signal confidence or potential shifts in strategy within the company.